J Korean Ophthalmol Soc > Volume 59(6); 2018 > Article
Journal of the Korean Ophthalmological Society 2018;59(6):511-518.
DOI: https://doi.org/10.3341/jkos.2018.59.6.511    Published online June 15, 2018.
Comparison of Short-term Clinical Outcomes between Oral Spironolactone and Observation in Acute Central Serous Chorioretinopathy.
Jong Young Lee, Dong Yoon Kim, Eun Kyoung Lee, Sang Yoon Lee, Hye Jin Lee, Jin Ho Jeong, Jin Young Kim
1Department of Ophthalmology, Jeju National University School of Medicine, Jeju, Korea. muse1016@naver.com
2Department of Ophthalmology, Jeju National University Hospital, Jeju, Korea.
3Department of Ophthalmology, Chungbuk National University College of Medicine, Cheongju, Korea.
4Department of Ophthalmology, Chungbuk National University Hospital, Cheongju, Korea.
급성 중심장액맥락망막병증에서 경구 스피로놀락톤과 단순 경과관찰의 단기 임상결과 비교
이종영1,2⋅김동윤3,4⋅이은경1,2⋅이상윤1,2⋅이혜진1,2⋅정진호1,2⋅김진영1,2
제주대학교 의학전문대학원 안과학교실1, 제주대학교병원 안과2, 충북대학교 의과대학 안과학교실3, 충북대학교병원 안과4
Correspondence:  Jin Young Kim,
Email: muse1016@naver.com
Received: 28 December 2017   • Revised: 2 March 2018   • Accepted: 28 May 2018
Abstract
PURPOSE
To compare the short-term efficacy of oral spironolactone vs. observation in patients with acute central serous chorioretinopathy. METHODS: Forty-seven eyes of 47 patients diagnosed as acute central serous chorioretinopathy from January 2013 to June 2016 were treated with oral spironolactone or were observed. This was a retrospective study involving patients analyzed for changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and subretinal fluid height (SRFH). RESULTS: Oral spironolactone was used to treat 24 eyes and 23 eyes were observed. There were no differences in baseline characteristics including age, sex, BCVA (logMAR), CMT, and SRFH between the two groups. The mean BCVA, CMT, and SRFH improved compared with baseline at 1 month and 2 months in both groups. In comparison between the two groups, the mean BCVA of oral spironolactone group improved more than in the observation group at 2 months (p = 0.006). There was a significant difference in CMT between the two groups at 1 month and 2 months (p = 0.017 and p < 0.001, respectively), and there was a significant difference in subretinal fluid height between the two groups at 2 months (p = 0.007). Complete resolution of subretinal fluid was achieved in 33.3% (8/24) and 21.7% (5/23) of the eyes in the oral spironolactone group and the observation group, respectively, at 2 months (p = 0.374). There was no serious side effect in patients treated with oral spironolactone. CONCLUSIONS: Both oral spironolactone and observation were effective for the treatment of acute central serous chorioretinopathy. Oral spironolactone was more effective than observation when comparing the best-corrected visual acuity, central macular thickness, and subretinal fluid height. As a noninvasive method for treatment of acute central serous chorioretinopathy, oral spironolactone showed anatomical improvement and improved visual acuity during a short-term period.
Key Words: Central serous chorioretinopathy;Observation;Spironolactone


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2020 by Korean Ophthalmological Society. All rights reserved.

Developed in M2community

Close layer
prev next